Chikungunya Outbreak in the Republic of the Congo, 2019—Epidemiological, Virological and Entomological Findings of a South-North Multidisciplinary Taskforce Investigation

The Republic of Congo (RoC) declared a chikungunya (CHIK) outbreak on 9 February 2019. We conducted a ONE-Human-Animal HEALTH epidemiological, virological and entomological investigation. Methods: We collected national surveillance and epidemiological data. CHIK diagnosis was based on RT-PCR and CHIKV-specific antibodies. Full CHIKV genome sequences were obtained by Sanger and MinION approaches and Bayesian tree phylogenetic analysis was performed. Mosquito larvae and 215 adult mosquitoes were collected in different villages of Kouilou and Pointe-Noire districts and estimates of Aedes (Ae.) mosquitos’ CHIKV-infectious bites obtained. We found two new CHIKV sequences of the East/Central/South African (ECSA) lineage, clustering with the recent enzootic sub-clade 2, showing the A226V mutation. The RoC 2019 CHIKV strain has two novel mutations, E2-T126M and E2-H351N. Phylogenetic suggests a common origin from 2016 Angola strain, from which it diverged around 1989 (95% HPD 1985–1994). The infectious bite pattern was similar for 2017, 2018 and early 2019. One Ae. albopictus pool was RT-PCR positive. The 2019 RoC CHIKV strain seems to be recently introduced or be endemic in sylvatic cycle. Distinct from the contemporary Indian CHIKV isolates and in contrast to the original Central-African strains (transmitted by Ae. aegypti), it carries the A226V mutation, indicating an independent adaptive mutation in response to vector replacement (Ae. albopictus vs Ae. aegypti)

Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking

Non-invasive ventilation during cycle exercise training in patients with chronic respiratory failure on long-term ventilatory support: A randomized controlled trial

The role of non-invasive ventilation (NIV) during exercise training (ET) in patients with chronic respiratory failure (CRF) is still unclear. The aim of this study was to test whether NIV during ET had an additional effect in increasing the 6-min walking distance (6MWD) and cycle endurance time compared with ET alone

Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases

A growing body of literature suggests that comprehensive Pulmonary Rehabilitation (PR) improves symptoms and functional capacity also in patients with Interstitial Lung Disease. Aim of this study was to investigate whether the baseline level of functional capacity or lung derangement, and ILD etiology may predict and affect outcomes\u2019 response to PR in these patients. MATERIALS AND METHODS Patients with ILD of different etiology were referred and prospectively admitted to PR, delivered according to a standardized protocol. Spirometry, Diffuse Lung Capacity for Carbon Monoxide [DLCO], incremental cyclo-ergometry test, Six Minutes Walking Distance Test [6MWDT], questionnaires on dyspnea and quality of life (St. George Respiratory Questionnaire-SGRQ, 5-point Medical Research Council scale-MRC) were assessed pre- and post- rehabilitation course; change from baseline of any measured variables was considered to assess the impact of PR on functional capacity, perceived symptoms and quality of life, respectively. Patients were stratified according to their level of DLCO, Forced Vital Capacity (FVC), 6MWTD, etiology (IPF or non-IPF), and GAP index (in IPF patients only). Analyses of changes from baseline and correlation test were conducted as appropriate. RESULTS Thirty-nine patients (mean age 66.87 \ub1 10.9 ys, IPF 62.5%) were enrolled and completed the PR course. 6MWDT (+54.3m, 95%CI 34.9-73.7, p < .0001), cycling time (+ 70.0%, p = .0009) and power (+60.4%, p= .008), iso-time dyspnea (-33.1%, p < .0001) and limb fatigue (-40.8%, p < .0001), SGRQ, MRC (p < .0001) significantly improved over time. Patients with lower baseline 6MWD showed greater change in 6MWD (Pearson r score = - .359, p = .034) and symptoms relief at SGRQ (r = -.229, p = .038). Different levels of FVC, DLCO, GAP index and etiology did not correlate with functional and symptoms outcomes. CONCLUSION Present study confirms that comprehensive rehabilitation is effective in patients with ILDs of different severity, and etiology and that baseline walking capacity inversely correlates with functional and symptom changes. Lung derangement or etiology does not affect outcomes following rehabilitation